Ebola Vaccine from GeoVax Offers 100% Protection in Rodent Trials

GeoVax Labs (OTCQB:GOVX) is a clinical-stage biotechnology company that develops human vaccines against infectious diseases using a novel platform technology. The company announced that its Ebola vaccine candidate GOVX-E301 has proven effective in rodent trials.
According to the press release:

GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

GeoVax’s Chief Scientific Officer Harriet L. Robinson said:

We are very pleased with the outcome of this study. Through our ongoing research, we have anticipated that GeoVax’s VLPs would elicit a strong immune response, and we had already demonstrated the production of Ebola VLPs in human cells. The next steps will be vaccination and challenge studies in nonhuman primates while also preparing for cGMP manufacturing of the vaccine for human clinical trials.

Click here to read the full press release from GeoVax.